These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 21697653)

  • 21. Macrophage regulation of tumor responses to anticancer therapies.
    De Palma M; Lewis CE
    Cancer Cell; 2013 Mar; 23(3):277-86. PubMed ID: 23518347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapies for solid tumors: current status and future perspectives.
    Stoffel A
    BioDrugs; 2010 Oct; 24(5):303-16. PubMed ID: 20649180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.
    Kim DG; Jin Y; Jin J; Yang H; Joo KM; Lee WS; Shim SR; Kim SW; Yoo J; Lee SH; Yoo JS; Nam DH
    MAbs; 2015; 7(6):1195-204. PubMed ID: 26325365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.
    Horn L; Sandler A
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S68-73. PubMed ID: 17382027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
    Bodoky G
    Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
    Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
    Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor.
    Adjei AA
    Clin Lung Cancer; 2007 Feb; 8 Suppl 2():S74-8. PubMed ID: 17382028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advances of VEGF related molecular promoting tumor angiogenesis and targeting therapy].
    Guo ZY; Cao BL
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):282-4. PubMed ID: 20654135
    [No Abstract]   [Full Text] [Related]  

  • 32. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapies in bladder cancer--an update.
    Black PC; Agarwal PK; Dinney CP
    Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C; Bani MR; Giavazzi R
    Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent advances in anti-angiogenic therapy of cancer.
    Samant RS; Shevde LA
    Oncotarget; 2011 Mar; 2(3):122-34. PubMed ID: 21399234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of angiogenesis inhibitors in prostate cancer.
    Aragon-Ching JB; Dahut WL
    Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic agents in breast cancer.
    Salter JT; Miller KD
    Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.